Skip to main content

Table 1 Characteristics of randomized clinical trials included in study

From: Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019

Author (Year) Trial Name Study Phase Phase Treatment Regimen No. Patients Median Age (Years) Median Duration of Treatment (Months)
Niesvizky (2015) [14] UPFRONT 3 ND Bortezomib/dexamethasone 165 74.5 6
     Bortezomib/thalidomide/dexamethasone 158 73 4.6
     Bortezomib/melphalan/prednisone 163 72 4.7
Richardson (2015) [33]   2 RR Elotuzumab/lenalidomide/dexamethasone 73 62 19.1
Mateos (2019) [15] ALCYONE 3 ND Daratumumab/bortezomib/melphalan/prednisone 346 71 13.5
Voorhees (2019) [16] GRIFFIN 2 ND Daratumumab/lenalidomide/bortezomib/dexamethasone 99 59 22.1
Usmani (2019) [38] KEYNOTE-185 3 RR Pembrolizumab/lenalidomide/dexamethasone 149 74 4.4
Mateos (2019) [40] COLUMBA 3 RR Subcutaneous daratumumab 260 65 7.5
     IV daratumumab 258 68 7.5
Spicka (2019) [34] ADMYRE 3 RR Plitidepsin/dexamethasone 167 64 3
Rosinol (2019) [17] PETHEMA/GEM2012 3 ND Bortezomib/lenalidomide/dexamethasone prior to transplant 458 58 6
Attal (2019) [35] ICARIA-MM 3 RR Isatuximab/pomalidomide/dexamethasone 152 68 10.2
Morgan (2019) [41] TOURMALINE-MM3 study 3 M Ixazomib maintenance 395 58 15.2
Moreau (2019) [36] BELLINI 3 RR Venetoclax/bortezomib/dexamethasone 194 66 18.7
Moreau (2019) [18] CASSIOPEIA 3 ND Daratumumab/bortezomib/melphalan/prednisone prior to and following transplant 536 59 8.9
Richardson (2019) [27] OPTISIMISMM 3 RR Bortezomib/pomalidomide/dexamethasone 278 67 8.8
Mateos (2019) [26] KEYNOTE-183 3 RR Pembrolizumab/pomalidomide/dexamethasone 120 65 4.1
Dimopoulos (2018) [30] POLLUX 3 RR Daratumumab/lenalidomide/dexamethasone 283 65 24.5
Jackson (2019) [24] Myeloma XI 3 ND Cyclophosphamide/bortezomib/dexamethasone induction 275 66 2.8
Horvath (2019) [19] VCAT 3 ND Bortezomib/thalidomide/prednisolone consolidation 103 58 10.2
Facon (2019) [23] CLARION 3 ND Carfilzomib/melphalan/prednisone 474 72 13.1
Facon (2019) [20] MAIA 3 ND Daratumumab/lenalidomide/dexamethasone 364 73 25.3
Lonial (2015) [25] ELOQUENT-2 3 RR Elotuzumab/lenalidomide/dexamethasone 318 67 17
Dimopoulos (2016) [37] ENDEAVOR 3 RR Carfilzomib 463 65 10
Spencer (2018) [31] CASTOR 3 RR Daratumumab/bortezomib/dexamethasone 243 64 13.4
Moreau (2018) [28] A.R.R.O.W. 3 RR Once weekly carfilzomib 238 66 9.5
     Twice weekly carfilzomib 235 66 7.3
Dimopoulos (2018) [29] ELOQUENT-3 2 RR Elotuzumab/pomalidomide/dexamethasone 60 69 8.4
Hajek (2016) [32] FOCUS 3 RR Carfilzomib 157 63 4.1
Durie (2017) [21] SWOG S0777 3 ND Bortezomib/lenalidomide/dexamethasone non-transplant 242 63 5.6
Bringhen (2019) [42] EMN01 3 M Lenalidomide maintenance 204 73 32.4
     Lenalidomide/prednisone maintenance 198 73 29.8
Zweegman (2016) [43] HOVON-NSMG 3 M Thalidomide maintenance 121 72 5
     Lenalidomide maintenance 124 73 17
Moreau (2016) [39]   3 RR Ixazomib/lenalidomide/dexamethasone 361 66 15.9
Jacobus (2016) [22] E1A05 3 NF Bortezomib/lenalidomide/dexamethasone consolidation, 23   4.55
Gay (2015) [44]   3 M Lenalidomide maintenance 117 57 28.9
     lenalidomide/prednisone maintenance 106 56 25.3